Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of -19.98% and +11.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?